Home›Insights›Article

Phenytoin Drug Interactions: A Complete Guide to Contraindicated and Serious Combinations

CDI
CDI AI Author
Reviewed against CDI's FDA-sourced database
📖 12 min read

What Are the Major Drug Interactions with Phenytoin?

Phenytoin is a strong inducer of the CYP3A4 enzyme system and other metabolic pathways, meaning it accelerates the breakdown of many other medications in your body. According to FDA-sourced labeling data, at least ten drug combinations with phenytoin are contraindicated—meaning the combination should be avoided entirely because the risk outweighs any potential benefit. The most serious contraindicated combinations involve blood thinners (rivaroxaban), psychiatric medications (clozapine, lurasidone), heart medications (nisoldipine, ticagrelor, ranolazine), a newer HIV treatment (doravirine), a long-acting HIV preventive (lenacapavir), an emergency contraceptive (estradiol valerate/dienogest), and an injectable enzyme (hyaluronidase). This guide explains each documented interaction, how phenytoin causes it, and what you should discuss with your pharmacist or doctor if you take phenytoin and any other medication.

What Is Phenytoin and How Does It Work?

Phenytoin is a long-established anticonvulsant (anti-seizure) medication used to prevent and control seizures in epilepsy and other conditions. It is also used to prevent seizures after certain surgical procedures or head injuries. Phenytoin works by stabilizing electrical activity in nerve cells, which reduces the tendency of neurons to fire repetitively and cause seizure activity.

A critical property of phenytoin that makes interaction management essential is its role as an enzyme inducer. Phenytoin activates—or "induces"—several drug-metabolizing enzyme systems, particularly the CYP3A4 family of enzymes in the liver. It also induces P-glycoprotein (P-gp), a transport protein that moves drugs out of cells. This means that when phenytoin is present in your body, it causes your liver and other tissues to break down and eliminate many other drugs much faster than they would normally be eliminated. As a result, the plasma concentrations (blood levels) of those other drugs drop significantly, often reducing their therapeutic effect or rendering them ineffective.

Phenytoin is available in immediate-release and extended-release formulations and is administered orally or intravenously depending on the clinical situation. Because of its potent enzyme-inducing properties, phenytoin interacts with a large number of medications, and careful medication review is essential before initiating phenytoin therapy or when phenytoin is already part of a treatment regimen.

Contraindicated Combinations: Drugs That Must Be Avoided with Phenytoin

The term "contraindicated" means the combination is not recommended and should be avoided. These ten combinations are classified as contraindicated based on FDA-sourced drug labeling because the interaction is severe enough that the risks are considered to outweigh any potential benefits.

Clozapine (Psychiatric Antipsychotic)

Clozapine is an atypical antipsychotic medication used to treat schizophrenia and other serious mental health conditions. According to FDA-sourced labeling, phenytoin is a strong CYP3A4 inducer that decreases clozapine plasma concentration. This means phenytoin accelerates clozapine's breakdown in the liver, causing clozapine levels to drop substantially. Because clozapine's effectiveness depends on maintaining adequate blood levels, this interaction results in decreased clozapine effectiveness. The source labeling states that concomitant use is not recommended. If a patient requires seizure control and is also being treated with clozapine, alternative anticonvulsant medications should be considered, and the prescribing physician should be consulted to explore other options.

Rivaroxaban (Blood Thinner)

Rivaroxaban is a direct Factor Xa inhibitor anticoagulant used to prevent blood clots and reduce the risk of stroke in patients with atrial fibrillation or after orthopedic surgery. According to FDA-sourced labeling, phenytoin is a combined P-glycoprotein and strong CYP3A inducer. This dual induction means phenytoin not only speeds up rivaroxaban's metabolism in the liver but also enhances the active transport of rivaroxaban out of cells, dramatically reducing rivaroxaban exposure. FDA labeling warns that this interaction may increase thromboembolic risk—meaning the risk that dangerous blood clots could form. The combination is listed as contraindicated, and alternative anticoagulant therapy should be considered if a patient requires phenytoin.

Lenacapavir Sodium (Long-Acting HIV Preventive)

Lenacapavir (marketed as Sunlicro) is a first-in-class HIV capsid inhibitor approved for the prevention of HIV in people at high risk and for treating HIV infection in treatment-experienced patients. According to FDA-sourced labeling, phenytoin is a CYP3A inducer that decreases lenacapavir concentration, resulting in loss of therapeutic effect and development of viral resistance. Because lenacapavir is a relatively new medication with a long dosing interval, maintaining therapeutic concentrations is critical. The interaction is contraindicated, and if a patient requires both lenacapavir and seizure control, alternative anticonvulsant therapy should be explored.

Nisoldipine (Calcium Channel Blocker for Hypertension)

Nisoldipine is a dihydropyridine calcium channel blocker used to treat high blood pressure. According to FDA-sourced labeling, phenytoin reduces nisoldipine plasma concentrations to undetectable levels through CYP3A4 induction. "Undetectable" means that nisoldipine blood levels become so low that the drug cannot be reliably measured and cannot exert its blood-pressure-lowering effect. The labeling states that coadministration should be avoided and that alternative antihypertensive therapy should be considered. This is a particularly striking example of phenytoin's enzyme-inducing power.

Ranolazine (Antianginal Agent)

Ranolazine is a piperazine derivative used to treat chronic angina (chest pain caused by reduced blood flow to the heart). According to FDA-sourced labeling, phenytoin is a CYP3A inducer, and the labeling explicitly states not to use ranolazine extended-release tablets with phenytoin. The induction of CYP3A4 results in decreased ranolazine exposure and reduced efficacy in preventing anginal episodes. If a patient requires both medications, the prescriber should consider alternative antianginal options.

Doravirine (Non-Nucleoside Reverse Transcriptase Inhibitor)

Doravirine (marketed as Pifeltro) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as a component of antiretroviral therapy for HIV-1 infection. According to FDA-sourced labeling, phenytoin co-administration decreases doravirine plasma concentrations through CYP3A induction. The labeling recommends at least a 4-week cessation period—that is, stopping phenytoin at least 4 weeks—prior to initiation of doravirine therapy to allow phenytoin levels to decline sufficiently. This extended washout period reflects the severity of the interaction and the time required for enzyme-inducing effects to diminish. Because effective HIV treatment depends on maintaining adequate doravirine levels, this combination is contraindicated without careful planning and medical supervision.

Estradiol Valerate/Dienogest (Emergency Contraceptive and Combined Oral Contraceptive)

Estradiol valerate/dienogest (marketed as Lo Loestrin Fe and other combinations) is a combined hormonal emergency contraceptive and regular oral contraceptive. According to FDA-sourced labeling, phenytoin is a strong CYP3A4 inducer that substantially reduces the effectiveness of this combination. The labeling warns that concomitant use should be avoided and specifically states that the combination should not be used while taking phenytoin or for 28 days after discontinuation of phenytoin. The 28-day washout period allows time for enzyme induction to reverse. The risk is decreased contraceptive efficacy, which could lead to unintended pregnancy. Patients requiring both seizure control and contraception should discuss alternative contraceptive methods (such as long-acting reversible contraception) or alternative anticonvulsants with their healthcare provider.

Ticagrelor (P2Y12 Platelet Inhibitor)

Ticagrelor is a P2Y12 platelet inhibitor used to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or a history of myocardial infarction. According to FDA-sourced labeling, phenytoin is a strong CYP3A inducer that substantially reduces ticagrelor exposure and decreases its efficacy. Because ticagrelor's antiplatelet effect is essential for preventing thrombotic events in high-risk cardiovascular patients, this interaction is contraindicated. If a patient requires both seizure control and antiplatelet therapy, alternative anticonvulsants or alternative antiplatelet agents should be explored in consultation with both the neurologist and cardiologist.

Lurasidone Hydrochloride (Atypical Antipsychotic)

Lurasidone is an atypical antipsychotic used to treat schizophrenia and bipolar depression. According to FDA-sourced labeling, phenytoin is a strong CYP3A4 inducer that decreases lurasidone exposure. The labeling states that concomitant use is contraindicated. Similar to clozapine, lurasidone requires maintenance of adequate blood levels for therapeutic effect, and CYP3A4 induction renders this impossible. Alternative anticonvulsants or alternative antipsychotics should be considered if both agents are clinically necessary.

Hyaluronidase, Ovine (Enzyme Injection)

Hyaluronidase, ovine (also known as Vitrase or Amphadase) is an injectable enzyme used to enhance the absorption and dispersion of other injected or infused substances. According to FDA-sourced labeling, there is a reported physical or chemical incompatibility between phenytoin and hyaluronidase. The source record does not specify a mechanism for this incompatibility. This interaction is listed as contraindicated, meaning phenytoin and hyaluronidase should not be co-administered or mixed in the same intravenous line. If hyaluronidase is required for a patient who is taking phenytoin, the drugs should be administered separately and the timing coordinated with careful medical supervision.

Understanding the Mechanism: CYP3A4 Induction

Nine of the ten contraindicated interactions documented above are caused by the same fundamental mechanism: CYP3A4 enzyme induction. CYP3A4 is a member of the cytochrome P450 family of enzymes, which are responsible for metabolizing the majority of drugs used in clinical practice. When phenytoin is present, it increases the expression and activity of CYP3A4, causing the liver and other tissues to break down CYP3A4 substrate drugs much more rapidly than normal.

This is a well-established feature of phenytoin pharmacology. Unlike some drug interactions, which occur only under specific circumstances or at high doses, CYP3A4 induction by phenytoin is robust and clinically significant at therapeutic doses. As a result, any drug that is significantly metabolized by CYP3A4 is at risk for reduced blood levels and reduced efficacy when combined with phenytoin.

Rivaroxaban is unique among the documented interactions in that it involves dual induction—both CYP3A4 metabolic induction and P-glycoprotein (P-gp) transporter induction. P-glycoprotein is an efflux transporter that actively pumps drugs out of cells and into the bloodstream for elimination. When phenytoin induces P-gp, it accelerates the removal of certain drugs from cells, further reducing their bioavailability and effect.

It is important to note that enzyme induction is not instantaneous. When phenytoin therapy is initiated, the enzyme-inducing effect develops over several days to weeks as the liver increases production of CYP3A4. Similarly, when phenytoin is discontinued, the induction effect takes time to wear off—typically 7 to 14 days or longer, which is why some labeling recommendations include washout periods of 28 days after phenytoin discontinuation.

Hypothetical Scenario 1: Anticoagulation After a Stroke

Imagine a patient who has suffered a stroke caused by atrial fibrillation. The stroke neurologist prescribes rivaroxaban to prevent future clots. Six months later, the patient develops epilepsy and begins phenytoin therapy. As phenytoin levels rise and CYP3A4 induction develops, rivaroxaban blood levels fall progressively. The patient has no way of knowing this is happening because there are no symptoms of low drug levels. However, the thromboembolic risk—the risk that a dangerous clot will form—increases silently. If the interaction is not caught by the healthcare team during a medication review, the patient could experience a second stroke. This scenario illustrates why a comprehensive medication check before starting any new drug is essential and why the interaction is labeled contraindicated rather than merely "monitor closely."

Hypothetical Scenario 2: HIV Prevention in a Young Woman

Consider a young woman prescribed lenacapavir for HIV prevention as part of a long-acting prevention regimen. She receives an injection every six months. One year into lenacapavir therapy, she experiences her first seizure and is started on phenytoin. Phenytoin induction begins to lower lenacapavir concentrations, gradually reducing the drug's protective effect. Over time, if the interaction is not recognized and addressed, the lenacapavir concentration could drop enough that HIV protection is no longer reliable. Additionally, the FDA labeling warns that reduced lenacapavir exposure could lead to the development of viral resistance, making future HIV treatments less effective. This underscores why the interaction is contraindicated and requires careful communication between all of her healthcare providers before phenytoin is initiated.

Summary of Contraindicated Drug Combinations with Phenytoin

Questions to Ask Your Pharmacist or Physician

If you are taking phenytoin or considering phenytoin therapy, and you take any other medications, here are key questions to raise with your healthcare team:

  1. "Is there an interaction between phenytoin and any of the medications I currently take?" Bring a complete list of all prescription drugs, over-the-counter medicines, supplements, and herbal products. Your pharmacist can cross-check against comprehensive interaction databases and FDA labeling.
  2. "If an interaction is identified, are there alternative medications I could use instead of phenytoin or instead of the interacting drug?" In many cases, alternative anticonvulsants with lower interaction potential may be available.
  3. "How long will it take for enzyme induction to develop after I start phenytoin, and how long will it persist after I stop?" Understanding the timeline helps you and your provider anticipate when dose adjustments of other medications might be necessary.
  4. "If I'm taking a contraindicated drug, should we stop one of them, switch to an alternative, or is there a special monitoring plan?" Do not make any changes on your own, but work with your prescriber to make a safe plan.
  5. "How will we monitor to make sure my other medications are still working effectively while I'm on phenytoin?" Some medications have measurable blood levels; others require clinical assessment of efficacy.
  6. "When I start or stop phenytoin, should the doses of my other medications be adjusted?" For medications whose efficacy depends on blood levels, dose adjustments may be needed as enzyme induction develops or resolves.

Key Takeaways

  • Phenytoin is a potent inducer of CYP3A4 enzymes and P-glycoprotein, causing it to accelerate the breakdown and elimination of many other drugs.
  • At least ten drug combinations with phenytoin are classified as contraindicated by FDA labeling. These include important medications for psychiatry (clozapine, lurasidone), cardiology (rivaroxaban, nisoldipine, ticagrelor, ranolazine), HIV treatment and prevention (doravirine, lenacapavir), contraception (estradiol valerate/dienogest), and an injectable enzyme (hyaluronidase).
  • Contraindicated means the combination should be avoided because the interaction is severe enough that the risks outweigh benefits. If you take phenytoin and any contraindicated drug, discuss alternatives and do not make changes without medical guidance.
  • CYP3A4 induction by phenytoin develops gradually over days to weeks and persists for days to weeks after phenytoin is stopped, which is why some labeling recommends washout periods of up to 28 days.
  • Always inform all of your healthcare providers—including your neurologist, primary care physician, pharmacist, cardiologist, and any specialists—that you take phenytoin, and review your medication list with them at every visit.

Sources

The interactions described in this article are drawn from FDA-sourced drug labeling as compiled in the NIH/NLM RxNorm and daily medication databases:

Individual drug labels (phenytoin, clozapine, rivaroxaban, lenacapavir, nisoldipine, ranolazine, doravirine, estradiol valerate/dienogest, ticagrelor, lurasidone, and hyaluronidase) were consulted via DailyMed. Mechanism descriptions reflect FDA labeling language and established pharmacological principles documented in peer-reviewed literature and FDA guidance.

Important Reminder: Check Your Medications and Consult Your Healthcare Team

The information in this guide is educational and explains documented interactions from FDA-sourced drug labeling. It is not a substitute for professional medical advice. If you take phenytoin and any other medication, visit checkdruginteractions.com to search your full medication list for interactions. Enter all of your drugs—including over-the-counter medicines, supplements, and herbal products—and review the results carefully. Then schedule a medication review appointment with your pharmacist or physician to discuss any interactions flagged, review whether alternatives are available, and ensure your treatment plan is safe and effective. Never start, stop, skip, or change any medication without first talking to your prescriber or pharmacist. If you experience any unusual symptoms while taking phenytoin and another medication, contact your healthcare provider immediately.

Check your medications
Check all your drug interactions at once

CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.

Check now →

Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.

Related Articles